Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , could offer a notable step forward for obesity treatment. Early clinical investigations have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-results-side-effects-cost